Samsung Biologics reports fourth quarter and fiscal year 2024 financial results
Recorded Q4'24 consolidated revenue of KRW 1.26 trillion Recorded FY'24 consolidated revenue of KRW 4.55 trillion Poised for further growth with expanded capacity and new service offerings INCHEON, South Korea, Jan. 22, 2025 /PRNewswire/ -- Samsung...
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
- The company to mark new phase of growth at Bio Campus II with the opening of Plant 5 in April - Samsung Biologics to offer ADC services and invest in advanced development and manufacturing capabilities to better address clients' needs INCHEON,...
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
Samsung Biologics to offer ADC services at new dedicated facility Extended collaboration reflects successful partnership and expertise INCHEON, South Korea, Jan. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract...